BIO-AVAILABILITY AND DISSOLUTION OF THREE PHENYTOIN PREPARATIONS FOR CHILDREN

Publisher Website
Google Scholar
Abstract
A study of bio-availability of three drug companies'' brands of phenytoin preparations (50 mg capsule/tablets) was undertaken on 30 children with tonic-clonic or complex partial seizures. Eight children were excluded because of non-compliance and three because of abnormally high serum levels. Phenytoin capsules (Parke Davis) and tablets (Boots) produced significantly higher serum-level profiles than phenytoin tablets (Evans). Seizure frequencies did not differ significantly with the three brands of phenytoin. Dissolution of the three preparations tested in vitro was different. As a result of this study the authors recommend that children remain on the same manufacturer''s brand of phenytoin throughout their treatment.

This publication has 4 references indexed in Scilit: